Physician profile
Charles E Mccathran
NPI 1043396625
$760.02
in general payments reported to CMS, 2019-2025
15 companies · $131 in 2025
The $131 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $40.03 · 2021: $31.37 · 2023: $57.99 · 2024: $52.41 · 2025: $131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $261.45 | 2019-2025 | |
| Hologic Sales and Service, LLC | $212.87 | 2019-2025 | Aptima |
| Shield Therapeutics INC | $36.26 | 2023-2024 | Accrufer |
| Coloplast Corp | $35.78 | 2019-2021 | |
| Avanos Medical | $30.62 | 2019 | |
| Karl Storz Endoscopy-America | $29.73 | 2019 | |
| Axsome Therapeutics, INC. | $29.32 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $28.95 | 2024-2025 | |
| Acell, INC. | $19.40 | 2019 | |
| Coopersurgical, INC. | $19.11 | 2023 | Mara Console |
| Astellas Pharma US INC | $18.24 | 2025 | Veozah |
| Covidien LP | $15.71 | 2019 | |
| Sumitomo Pharma America, INC. | $13.99 | 2025 | Myfembree |
| Organon LLC | $5.43 | 2023 | Nexplanon |
| Evofem Biosciences, INC. | $3.16 | 2025 | Solosec, Phexx, Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mccathran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.